

Go 11653/1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re Application of: NOV 2 1 2002

Hateboer et al. TECH CENTER 1600/2900

CERTIFICATE OF MAILING

Filed: April 14, 2000

Thereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents. Washington, D.C. 20231.

Confirmation No.: 8657

Examiner: R. Mitra

Serial No.: 09/549,463

Group Art Unit: 1653

Attorney Docket No.: 2183-4038.1US

mber 13, 2002 Signature

Betty Vowles
Name (Type/Print)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 or PTO/SB/08 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

11/20/2002 ADSMAN1 00000125 09549463

01 FC:1806

180.00 OP



U.S. Patent Documents

U.S. Patent No. Publication Date Patentee
US - 5,994,128 11-30-1999 Fallaux et al.

Foreign Patent Documents

Document No.	Publication Date	<u>Patentee</u>	
WO 93/03163	02-18-1993	Fond Nat Transfusion	
WO 97/00326	01-03-1997	Univ Leiden	
WO 95/29994	11-09-1995	Univ Michigan	
EP 0 185 573	06-25-1986	Pasteur Institut	

Other Documents

PCT International Search Report, PCT/NL00/00247, dated October 9, 2000, 3 pages.

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56 & 1.175, applicant hereby identifies the following listed copending applications naming the same inventor(s):

Attorney Docket No.: 2578-3840US Serial No.: 09/065,752

Filing Date:

4/24/1998

Title:

PACKAGING SYSTEMS FOR HUMAN RECOMBINANT

ADENOVIRUS TO BE USED IN GENE THERAPY

Attorney Docket No.: 2887-3836US Serial No.: 09/097,239

Filing Date:

6/12/1998

Title:

HIGH THROUGHPUT SCREENING OF GENE FUNCTION

USING ADENOVIRAL LIBRARIES FOR FUNCTIONAL

GENOMICS APPLICATIONS

Attorney Docket No.: 2183-4230US

Serial No.:

09/214,836 10/4/1999

Filing Date: Title:

MELANOMA ASSOCIATED PEPTIDE ANALOGUES AND

VACCINES AGAINST MELANOMA

Attorney Docket No.:

2183-4075US 09/332,803

Serial No.: Filing Date:

6/14/1999

Title:

PACKAGING SYSTEMS FOR HUMAN RECOMBINANT

ADENOVIRUS TO BE USED IN GENE THERAPY

Attorney Docket No.:

2578-4123.2US

Serial No.:

09/348,354

Filing Date:

7/7/1999

Title:

CHIMAERIC ADENOVIRUSES

Attorney Docket No.:

2183-4231US

Serial No.: Filing Date: 09/444,284 11/19/1999

Title:

GENE DELIVERY VECTORS PROVIDED WITH A TISSUE

TROPISM FOR SMOOTH MUSCLE CELLS, AND/OR

ENDOTHELIAL CELLS

Attorney Docket No.:

2183-4240US

Serial No.:

09/449,854

Filing Date:

11/26/1999

Title:

PRODUCTION OF VACCINES

Attorney Docket No.: 2183-4215US

Serial No.:

09/481,201

Filing Date:

1/11/2000

Title:

INTERLEUKIN-3 GENE THERAPY FOR CANCER

Attorney Docket No.: 2183-4318US

Serial No.:

09/502,624

Filing Date:

2/11/2000

Title:

VECTORS AND METHODS FOR PROVIDING CELLS WITH

ADDITIONAL NUCLEIC ACID MATERIAL INTEGRATED IN

THE GENOME OF SAID CELLS

Attorney Docket No.:

2578-3833.3US

Serial No.:

09/506,548

Filing Date:

2/16/2000

Title:

PACKAGING SYSTEMS FOR HUMAN RECOMBINANT

ADENOVIRUS TO BE USED IN GENE THERAPY

Attorney Docket No.:

2183-3982.2US

Serial No.:

09/517,898

Filing Date:

3/3/2000

Title:

MEANS AND METHODS FOR FIBROBLAST-LIKE OR

MACROPHAGE-LIKE CELL TRANSDUCTION

Attorney Docket No.:

2183-4070.1US

Serial No.:

09/573,740

Filing Date:

5/18/2000

Title:

SEROTYPES OF ADENOVIRUS AND USES THEREOF

Attorney Docket No.:

2183-4497US

Serial No.:

09/621,593

Filing Date:

7/21/2000

Title:

MEANS AND METHODS FOR RAISING ANTIBODY

CONCENTRATION IN COMPARTMENTS OF THE BODY OF A

NON HUMAN ANIMAL

Attorney Docket No.:

2183-4192.1US

Serial No.:

09/657,492

Filing Date:

9/8/2000

Title:

MODIFIED ADENOVIRAL VECTORS FOR USE IN GENE

THERAPY

Attorney Docket No.:

2578-4489US

Serial No.:

09/665,472

Filing Date:

9/20/2000

Title:

GENE DELIVERY VECTORS PROVIDED WITH A TISSUE

TROPISM FOR DENDRITIC CELLS

Attorney Docket No.:

2183-4626US

Serial No.:

09/722,867

Filing Date:

11/27/2000

Title:

PRODUCTION OF VACCINES

Attorney Docket No.:

2183-4843US

Serial No.:

09/843,894

Filing Date:

4/27/2001

Title:

AAV VECTOR PRODUCTION

Attorney Docket No.:

2578-3840.1US

Serial No.:

09/900,062

Filing Date:

7/6/2001

Title:

PACKAGING SYSTEMS FOR HUMAN RECOMBINANT

ADENOVIRUS TO BE USED IN GENE THERAPY

Attorney Docket No.:

2578-3935.1US

Serial No.:

09/912,552

Filing Date:

7/23/2001

Title:

PACKAGING SYSTEMS FOR HUMAN RECOMBINANT

ADENOVIRUS TO BE USED IN GENE THERAPY

Attorney Docket No.:

2578-3833.5US

Serial No.:

09/918,029

Filing Date:

7/30/2001

Title:

PACKAGING SYSTEMS FOR HUMAN RECOMBINANT

ADENOVIRUS TO BE USED IN GENE THERAPY

Attorney Docket No.:

2578-4509.1US

Serial No.:

09/928,262

Filing Date:

8/10/2001

Title:

GENE DELIVERY VECTORS WITH CELL TYPE SPECIFICITY

FOR PRIMARY HUMAN CHONDROCYTES

Attorney Docket No.:

2578-4123.1US

Serial No.:

09/953,280

Filing Date:

9/14/2001

Title:

CHIMAERIC ADENOVIRUSES

Attorney Docket No.:

2183-5006.1US

Serial No.:

10/010,645

Filing Date:

11/13/2001

Title:

GENE DELIVERY VECTORS WITH CELL TYPE SPECIFICITY

FOR MESENCHYMAL STEM CELLS

Attorney Docket No.:

2578-3833.6US

Serial No.:

10/038,271

Filing Date:

10/23/2001

Title:

PACKAGING SYSTEMS FOR HUMAN RECOMBINANT

ADENOVIRUS TO BE USED IN GENE THERAPY

Attorney Docket No.:

2578-3833.7US

Serial No.:

10/125,751

Filing Date:

4/18/2002

Title:

PACKAGING SYSTEMS FOR HUMAN RECOMBINANT

ADENOVIRUS TO BE USED IN GENE THERAPY

Attorney Docket No.:

2578-3955.1US

Serial No.:

10/136,139

Filing Date:

5/1/2002

Title:

MEANS AND METHODS FOR NUCLEIC ACID DELIVERY

VEHICLE DESIGN AND NUCLEIC ACID TRANSFER

Attorney Docket No.:

2578-4451.1US

Serial No.:

10/196,688

Filing Date:

7/15/2002

Title:

ADENO-ASSOCIATED VIRUS AND ADENOVIRUS CHIMERIC

RECOMBINANT VIRUSES USEFUL FOR THE INTEGRATION

OF FOREIGN GENETIC INFORMATION INTO CHROMOSOMAL DNA OF TARGET CELLS

Attorney Docket No.:

2578-3833.8US

Serial No.:

10/219,414

Filing Date:

8/15/2002

Title:

STOCKS OF REPLICATION DEFICIENT ADENOVIRUS

Attorney Docket No.:

2578-4215.1US

Serial No.:

10/231,735

Filing Date:

8/28/2002

Title:

INTERLEUKIN-3 GENE THERAPY FOR CANCER

Attorney Docket No.:

2578-4038.2US

Serial No.:

10/234,007

Filing Date:

9/3/2002

Title:

RECOMBINANT PROTEIN PRODUCTION IN A HUMAN CELL

This Information Disclosure Statement is filed after the mailing date of a first Office Action on the merits.

The fee pursuant to 37 C.F.R. § 1.17(p) is enclosed.

Respectfully submitted,

Allen C. Turner

Registration No. 33,041 Attorney for Applicant(s)

TRASKBRITT, PC

P.O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: 801-532-1922

Date: November 13, 2002

ACT/bv

Enclosures: Form PTO-1449 or PTO/SB/08

Cited Documents

Document in ProLaw

Approved for use through 10 31 2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

OMB 0651-0031
OF COMMERCE ———
MB control number.

And Management of the Annual Pro-

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2 Attorney Docket Number 2183-4038.1USTECH CENTER 1800/290

U.S. PATENT DOCUMENTS

Examiner Of Patentee or Applicant of Cited Document Number Publication Date MM-DD-YYYY

MM-DD-YYYY

MM-DD-YYYY

MM-DD-YYYY

Passages or Relevant Passages or Relevant

	1		U.S. PATENT D	· · · · · · · · · · · · · · · · · · ·	
Examiner Initials *	Cite No.1	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-5.994.128	11-30-1999	Fallaux et al.	
		US-			
		US-			
		US-			
	L	US-			
		US-			· · · · · · · · · · · · · · · · · · ·
		US-			
		US-			
		US-	.=		
		US-			

Examiner Cite Initials* No.1	Cite	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	Country Code ¹ - Number ⁴ - Kind Code ⁵ (if known)					
		WO 93 03163	02-18-1993	Fond Nat Transfusion		
		WO 97/00326	01-03-1997	Univ Leiden		
		WO 95/29994	11-09-1995	Univ Michigan		
		EP 0 185 573	06-25-1986	Pasteur Institut		

Examiner Signature	_	Dai Co	nsidered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ³ Applicant is to place a check mark here if English language Translation is attached

PTO	SR	()XR(10-01:	١

Approved for use through 10 31 2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 09/549,463

Filing Date April 14, 2000

First Named Inventor Hateboer et al. NOV 2 I 2000

Group Art Unit 1653

Examiner Name R. Mitra TECH CENIER 1600/2

(use as many sheets as necessary)

Examiner Initials * OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue numberts).

PCT International Search Report, PCT NL00 00247, dated October 9, 2000, 3 pages.

PCT International Search Report, PCT NL00 00247, dated October 9, 2000, 3 pages.

Date
Examiner
Signature

Date
Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents. Washington, DC 20231.



EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.